Aspartate Aminotransferase-to-platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis

In brief

This meta-analysis evaluates the APRi score as a non-invasive alternative to liver biopsy for assessing fibrosis severity in pediatric biliary atresia patients. The study addresses gaps in standardized diagnostic criteria and examines APRi accuracy across diverse patient populations, providing evidence for clinical decision-making in this severe pediatric liver condition.

• APRi is a non-invasive biomarker that may replace liver biopsy for assessing fibrosis severity in pediatric biliary atresia patients.
• Biliary atresia progresses to cirrhosis without prompt intervention, making early fibrosis assessment critical for treatment decisions.
• Standardized APRi cutoff values for pediatric BA populations are not yet established, limiting clinical implementation across diverse cohorts.

Written by the GCMD Library team from the article.